SCHEMBL4353115

SCHEMBL4353115

Cc1noc(C)c1-c1nc(COc2ccc(C[C@H]3[C@@H](CN(CC(C)C)S(=O)(=O)c4ccc5c(c4)OCO5)OC(C)(C)N3C(=O)O)cc2)no1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.38
S1PR1 P21453 1/20 0.36
HTT P42858 2/20 0.35
LMNA P02545 2/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
FFAR1 O14842 4/20 0.34
TSHR P16473 3/20 0.34
ALDH1A1 P00352 3/20 0.34
POLB P06746 1/20 0.33
ESR2 Q92731 1/20 0.33
PPARG P37231 2/20 0.32
PPARD Q03181 2/20 0.32
PPARA Q07869 2/20 0.32
KDM4E B2RXH2 1/20 0.32
GAA P10253 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4354092 0.89 LMNA (0.41) ABCB1S1PR1HTTLMNAALDH1A1
SCHEMBL4349451 0.89 TSHR (0.41) ABCB1HTTLMNAMEN1KMT2A
SCHEMBL6051172 0.88 ABCB1 (0.50) ABCB1S1PR1HTTLMNAMEN1
SCHEMBL4341116 0.87 LMNA (0.37) ABCB1S1PR1HTTLMNAMEN1
SCHEMBL4347227 0.84 ADAMTS4 (0.46) ABCB1HTTLMNAMEN1KMT2A
SCHEMBL4352479 0.83 MMP13 (0.40) ABCB1HTTLMNAMEN1KMT2A
SCHEMBL4347715 0.83 LMNA (0.40) ABCB1HTTLMNAMEN1KMT2A
SCHEMBL4353025 0.83 ADAMTS4 (0.40) ABCB1HTTLMNAMEN1KMT2A
SCHEMBL4341082 0.83 LMNA (0.40) ABCB1HTTLMNAMEN1KMT2A
SCHEMBL4340203 0.82 MAOB (0.39) ABCB1HTTLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2009-11-05 US disclosed
EP-1194404-B1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMA (US) 2006-05-03 EP disclosed
US-6878728-B1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICAL INCORPORATED (US) 2005-04-12 US disclosed
US-20040122000-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED. 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122000-A1 Inhibitors of aspartyl protease SPINT2, DNPEP, PRSS1 ABCB1 628/4885S1PR1 3645/4885HTT 1847/4885
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE SPINT2, DNPEP, PRSS1 ABCB1 628/4885S1PR1 3645/4885HTT 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.